A phase II study of the effects of Herceptin [trastuzumab] in patients with locally advanced HER-2/NEU overexpressing breast cancer.
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Trastuzumab (Primary) ; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 May 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2012as reported by ClinicalTrials.gov.